Oxford BioMedica PLC (OXB)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

629.00p

Buy

635.00p

arrow-down-15.00p (-2.34%)

Prices updated at 12 Dec 2025, 17:00 GMT

Prices minimum 15 mins delay

Prices in GBX

Oxford BioMedica PLC is a biopharmaceutical company based in the United Kingdom. It develops gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Roch F. Doliveux

CEO

Dr. Frank Mathias

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

900

Head office

Windrush Court

Oxford

United Kingdom

OX4 6LT

+44 1865783000

enquiries@oxb.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Professor Dame Kay Davies Non-Executive Director, Senior Independent Director	-
Dr. Roch F. Doliveux Non-Executive Director, Chairman	-
Dr. Heather Elizabeth Preston, M.D. Non-Executive Director	-
Ms. Namrata P Patel Non-Executive Director	-
Ms. Lucinda Crabtree Executive Director, Chief Financial Officer	-
Dr. Frank Mathias Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
M&G Investment Management Limited	6,185,114
M&G Recovery Fund	5,524,282
Zurich Ltd.	2,097,679
BlackRock Smaller Companies	1,851,346
Liontrust Fund Partners LLP	1,787,367

Director dealings

Date chevron-l-regular chevron-r-regular	Action
20 Oct 2025	Purchase
18 Aug 2025	Sale
15 Aug 2025	Purchase
11 Aug 2025	Purchase
17 Jun 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.